search

Active clinical trials for "Osteosarcoma"

Results 261-270 of 369

Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of...

Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorMetastatic Osteosarcoma7 more

This phase II trial is studying how well sorafenib works in treating patients with soft tissue sarcoma. Sorafenib may stop the growth of soft tissue sarcoma by blocking blood flow to the tumor and blocking some of the enzymes needed for tumor cell growth

Completed23 enrollment criteria

Irinotecan in Treating Children With Refractory Solid Tumors

Childhood Central Nervous System Germ Cell TumorChildhood Choroid Plexus Tumor20 more

This phase II trial is studying irinotecan to see how well it works in treating children with refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Completed51 enrollment criteria

Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma

Childhood Malignant Fibrous Histiocytoma of BoneSarcoma

RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have metastatic or unresectable locally advanced soft tissue sarcoma or bone sarcoma.

Completed47 enrollment criteria

ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors

GlioblastomaRhabdomyosarcomas2 more

The purpose of this Phase I study is to find the largest dose of the drug irinotecan, in combination with ZD1839, that can be given safely to children and to learn the good and bad effects. Studies performed in the laboratory have shown that ZD1839 helps make available the orally administered irinotecan. In this study the intravenous (given into the vein) formula of irinotecan will be given orally on days 1-5 and days 8-12. The dose of ZD1839 will be a fixed dose and will be administered orally on days 1-12. Each course of treatment will consist of 21 days. The administration of irinotecan on day 12 of course 1 and day 2 of course 2 will be an intravenous administration. All other doses and subsequent courses will consist of an orally administered dose.

Completed12 enrollment criteria

Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors...

Previously Treated Childhood RhabdomyosarcomaRecurrent Childhood Brain Tumor10 more

This phase I trial is studying the side effects and best dose of erlotinib when given with temozolomide in treating young patients with recurrent or refractory solid tumors. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving erlotinib with temozolomide may kill more tumor cells.

Completed59 enrollment criteria

Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma

Sarcoma

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have previously treated metastatic osteosarcoma.

Completed3 enrollment criteria

Open-label Leucovorin Pharmacokinetic Study in Patients Receiving High Dose Methotrexate With or...

OsteosarcomaLeukemia1 more

The purpose of this study is to investigate whether the administration of Voraxaze reduces exposure to leucovorin and its active metabolite to below the level achieved in patients who have not received Voraxaze.

Completed5 enrollment criteria

Comparison of High-Dose Methotrexate (HDM) Plus Doxorubicin to HDM Plus Etoposide-Ifosfamide in...

OsteosarcomaLocalised High Grade Osteosarcoma of the Limbs

The purpose of this study is to compare two preoperative chemotherapy regimens based on high-dose methotrexate courses given alternately either with doxorubicin or with etoposide-ifosfamide.

Completed11 enrollment criteria

Sorafenib in Relapsed High Grade Osteosarcoma

Osteosarcoma

Aim of this exploratory phase II study is to assess the clinical activity of sorafenib as single agent, in terms of percentage of patients with high grade advanced osteosarcoma free from progression following 4 months of therapy

Completed17 enrollment criteria

Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and...

Osteosarcoma

The study is designed to determine if the administration of multi-drug adjuvant chemotherapy for patients with primary non-metastatic osteogenic sarcoma, both prior to and after the definitive surgical procedure for their primary tumor is superior as a treatment strategy to the current approach of giving drugs only after the definitive surgical procedure has been performed. An effort will be made as well to determine if the administration of pre-definitive surgery, chemotherapy leads to an increase in the proportion of the patients suitable for a limb salvage primary surgical procedure.

Completed11 enrollment criteria
1...262728...37

Need Help? Contact our team!


We'll reach out to this number within 24 hrs